Back in 2013, Actelion launched Opsumit, a new-and-improved pulmonary arterial hypertension (PAH) drug it hoped would help make up sales for its aging Tracleer. And so far, everything is going according to plan.
The med pulled in CHF 147 million ($154 million) for the Swiss biotech in Q3, trumping the CHF 125 million analysts had predicted. “The launch momentum for Opsumit continues unabated,” CFO Andre Muller told Reuters.
It’s a good time for Opsumit to be hitting its stride. Sales of PAH predecessor Tracleer fell 17% to CHF 289 million for the period–about where analysts thought they’d be, the news service reports.
But with Opsumit picking up the slack, the company thinks it’s in good shape. It revised its growth forecast for the year, announcing that it now expects core earnings expansion to top 20%, up from the mid- to high-teens jump it last predicted.
As such, Actelion doesn’t “need M&A,” it’s CEO, Jean-Paul Clozel, told Reuters, pointing out that pickups were “not a fundamental aspect of our strategy.”
But that hasn’t kept the company out of many an M&A rumor. Back in September, it confirmed that it was in strategic talks with Texas’ ZS Pharma, and it’s in regular discussions with “7 or 8” companies over possible tie-ups. Actelion has the capacity to make a buy bigger than $2.5 billion, Muller said, though it won’t pull the trigger without good reason.
But Opsumit’s hot start could attract buyers, too. Earlier this year, word on the street was that deal-hungry Shire was eyeing a deal, sending Actelion’s shares up past CHF 147. Since then, though, Shire has made a play for young Baxter spinoff Baxalta, and Clozel told Reuters Actelion hasn’t been approached by shoppers.
By Carly Helfand
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
